A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Phase 2a Study of the Efficacy and Safety of a Bispecific Fusion Protein (MEDI7352) Targeting NGF and TNFα in Patients with Painful Diabetic Neuropathy

Kirsten M. Scott, Ola Adamson, Tharani Chessell, Edward Emery, Ali Guermazi, David Howe, Richard Jenkins, Jenny Lamport, Mene Pangalos, Thomas Schnitzer, Keith Tan, Isabelle Pouliquen, Fraser Welsh, Thor Ostenfeld, Ekaterina Podchufarova, Mark A. Pilling, Nigel Brayshaw, Iain Chessell
doi: https://doi.org/10.1101/2025.11.27.25341159

Article usage

Article usage: November 2025 to May 2026

AbstractFullPdf
Nov 2025182037
Dec 202530273165
Jan 20262784037
Feb 202615553104
Mar 20264235946
Apr 2026723539
May 2026664254
Back to top
Posted November 30, 2025.
Download PDF
Data/Code
Email
A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Phase 2a Study of the Efficacy and Safety of a Bispecific Fusion Protein (MEDI7352) Targeting NGF and TNFα in Patients with Painful Diabetic Neuropathy
Kirsten M. Scott, Ola Adamson, Tharani Chessell, Edward Emery, Ali Guermazi, David Howe, Richard Jenkins, Jenny Lamport, Mene Pangalos, Thomas Schnitzer, Keith Tan, Isabelle Pouliquen, Fraser Welsh, Thor Ostenfeld, Ekaterina Podchufarova, Mark A. Pilling, Nigel Brayshaw, Iain Chessell
medRxiv 2025.11.27.25341159; doi: https://doi.org/10.1101/2025.11.27.25341159
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area